{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:30Z","timestamp":1777934610866,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Premedication of cancer therapy against nausea and vomiting (NV) and hypersensitivity reaction (HS) is essential for good patient management. However, this prescription is not always optimal. Today, as a large part of cancer therapies are administered in day hospitals (DH), premedication taken on the day of the cancer treatment is injected as a 30-min infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess compliance with recommendations for premedication prescription and intake; to analyse patient attitude about switching to exclusively oral forms taken at home.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>The study is conducted in the medical oncology DH of a French Hospital from 17 January to 25 February 2022. The data collection is carried out as an individual interview, associated with the distribution of two questionnaires. Data are coupled with the premedication set up on our software and the last medical report. Intakes are considered optimal when recommendations, tolerance, background, and adherence of the patient are taken into account.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy patients were included for interviews. Regarding software prescriptions, our configuration was consistent with recommendations in 100% of cases for HS and 37% for NV. Intakes were compliant in 51.4% of cases, non-compliant in 17.1% and debatable in 31.5%. Disparities between the practices of different physicians were identified. Regarding the feasibility of oral substitution, it could concern 63.5% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This work makes it possible to improve the management of all patients and to make the operation of the care unit more fluid.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231168314","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T01:33:30Z","timestamp":1681176810000},"page":"88-99","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Overview of premedication prescription and intake in an oncology day hospital: What do we need to change to improve patient management?"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1291-3467","authenticated-orcid":false,"given":"Annabel","family":"Goubil","sequence":"first","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Pharmacie, F-44000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurine","family":"Lallier","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Pharmacie, F-44000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Peyrilles","sequence":"additional","affiliation":[{"name":"Cancer Institute Paul Papin, Pharmacie, Angers, 49000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahna","family":"Coupez","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Oncology, F-44000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christ\u00e8le Le","family":"Gouill","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Oncology Day Hospital, F-44000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Fronteau","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Pharmacie, F-44000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Cormier","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Pharmacie, F-44000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"bibr1-10781552231168314","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"bibr2-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102019"},{"key":"bibr3-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278"},{"key":"bibr4-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1016\/j.emc.2014.04.006"},{"key":"bibr5-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-001-0339-7"},{"key":"bibr6-10781552231168314","first-page":"1601","volume":"66","author":"Wilcox PM","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"bibr7-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515442"},{"key":"bibr8-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08932-2"},{"key":"bibr9-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4464-y"},{"key":"bibr10-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2019.02.002"},{"key":"bibr11-10781552231168314","unstructured":"RCP PACLITAXEL HOSPIRA 6 mg\/ml, solution \u00e0 diluer pour perfusion."},{"key":"bibr12-10781552231168314","unstructured":"RCP DOCETAXEL ACCORD 20 mg\/ml, solution \u00e0 diluer pour perfusion."},{"key":"bibr13-10781552231168314","unstructured":"RCP CYRAMZA 10 mg\/mL, solution \u00e0 diluer pour perfusion. 2020."},{"key":"bibr14-10781552231168314","unstructured":"RCP ERBITUX 5 mg\/mL, solution \u00e0 diluer pour perfusion."},{"key":"bibr15-10781552231168314","unstructured":"RCP BAVENCIO 20 mg\/ml, solution \u00e0 diluer pour perfusion."},{"key":"bibr16-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.09.073"},{"key":"bibr17-10781552231168314","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7526"},{"key":"bibr18-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1079-3"},{"key":"bibr19-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1111\/all.15113"},{"key":"bibr20-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx100"},{"key":"bibr21-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X46313"},{"key":"bibr22-10781552231168314","unstructured":"InCa. Panorama des cancers en France-\u00e9dition 2022 [Internet]. Disponible sur: https:\/\/www.e-cancer.fr\/Patients-et-proches\/Les-cancers\/Cancer-du-rein\/Points-cles."},{"key":"bibr23-10781552231168314","unstructured":"Qu\u00e9bec (Province), Comit\u00e9 de l\u2019\u00e9volution des pratiques en oncologie, Almanric K Direction qu?b?coise de canc?rologie. Prise en charge de l\u2019hypersensibilit\u00e9 associ\u00e9e aux chimioth\u00e9rapies \u00e0 base de sels de platines et de taxanes [Internet]. 2013 [cit\u00e9 9 avr 2022]. Disponible sur: http:\/\/collections.banq.qc.ca\/ark:\/52327\/2293521"},{"key":"bibr24-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.019448"},{"key":"bibr25-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2011.10.004"},{"key":"bibr26-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601155"},{"key":"bibr27-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11901"},{"key":"bibr28-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11379"},{"key":"bibr29-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s005200100273"},{"key":"bibr30-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-813741"},{"key":"bibr31-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.04.009"},{"key":"bibr32-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01200"},{"key":"bibr33-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1177\/0300060517713531"},{"key":"bibr34-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1278-6"},{"key":"bibr35-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06734-4"},{"key":"bibr36-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558272"},{"key":"bibr37-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(90)90091-H"},{"key":"bibr38-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11760147"},{"key":"bibr39-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12495"},{"key":"bibr40-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6546"},{"key":"bibr41-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05791-5"},{"key":"bibr42-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0511-4"},{"key":"bibr43-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1188\/03.ONF.259-271"},{"key":"bibr44-10781552231168314","first-page":"211","volume":"5","author":"Vidall C","year":"2011","journal-title":"Ecancermedicalscience"},{"key":"bibr45-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-003-0553-6"},{"key":"bibr46-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2136-0"},{"key":"bibr47-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1969-2"},{"key":"bibr48-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055473"},{"key":"bibr49-10781552231168314","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.771"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231168314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231168314","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231168314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:13Z","timestamp":1777688893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231168314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1177\/10781552231168314"],"URL":"https:\/\/doi.org\/10.1177\/10781552231168314","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]}}}